Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 7/20 | 0.47 |
| ▸ | PARP1 | P09874 | 6/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 4/20 | 0.47 |
| ▸ | CCR3 | P51677 | 3/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.40 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4079404 | 0.93 | PARP1 (0.43) | TNKSPARP1TNKS2CCR3JAK2 | |
| SCHEMBL4076737 | 0.87 | TSHR (0.44) | TNKSPARP1TNKS2CCR3HTR2A | |
| SCHEMBL4068281 | 0.86 | CCR3 (0.49) | PARP1CCR3 | |
| SCHEMBL4078598 | 0.86 | CCR3 (0.52) | PARP1CCR3HTR2A | |
| SCHEMBL4073316 | 0.85 | OPRM1 (0.48) | TNKSPARP1TNKS2HTR2AHTR6 | |
| SCHEMBL4078326 | 0.84 | PARP1 (0.48) | TNKSPARP1TNKS2CCR3HTR2A | |
| SCHEMBL4069626 | 0.84 | HTR2A (0.56) | TNKSPARP1TNKS2HTR2A | |
| SCHEMBL4075963 | 0.83 | CCR3 (0.46) | PARP1CCR3 | |
| SCHEMBL4080486 | 0.83 | CCR3 (0.46) | PARP1CCR3HTR2A | |
| SCHEMBL4073519 | 0.80 | CCNT1 (0.39) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | claimed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | claimed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | claimed |
| US-7501412-B2 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-03-10 | — | — | US | disclosed |
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1566380-A1 | ISOQUINOLINE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2005-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094743-A1 | Isoquinoline compounds and medicinal use thereof | PARP1, NQO1, PARP3 | TNKS 127/4885PARP1 1/4885TNKS2 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.